Onera Health, a startup specializing in sleep diagnostic and monitoring technology, has secured €30 million ($32 million) in a Series C funding round.
Addressing a Significant Health Issue
Sleep disorders have substantial economic and health implications, with estimates suggesting that poor sleep costs the U.S. economy around $400 billion annually. Factors such as absenteeism and reduced productivity due to sleep-related issues underscore the need for effective diagnostic and monitoring solutions.
Clinical-Grade Sleep Monitoring
While numerous sleep-tracking devices exist, Onera distinguishes itself by offering a clinical-grade solution. The company has obtained regulatory clearance from authorities such as the Food and Drug Administration (FDA) in the U.S., positioning its technology as a trusted option for healthcare professionals. Onera’s innovative approach enables clinicians to conduct polysomnography (PSG) studies directly in patients’ homes or in laboratory settings, if necessary.
Streamlined Process
Onera’s platform streamlines the sleep study process. Clinicians initiate a PSG study through Onera, which then ships the required sensors directly to the patient. These sensors, comprising wireless devices attached to specific body areas, are easily connected by the patient following simple instructions. Once the study is complete, the patient returns the hardware to Onera, where the data is processed in the company’s cloud platform. Onera generates a comprehensive report for the clinician to evaluate, facilitating diagnosis and treatment planning.
Future Expansion and Innovation
Founded in the Netherlands in 2017, Onera has raised a total of €55 million in funding. The recent Series C round was co-led by EQT Life Sciences and Gimv, with participation from other investors including Innovation Industries, Invest-NL, Imec.xpand, BOM, and 15th Rock. With the infusion of €30 million from the latest funding round, Onera aims to accelerate the regulatory clearance process for its second-generation PSG system in both the U.S. and European markets. Currently serving the Benelux and DACH regions, the company plans to expand its geographic reach and invest further in research and development to address the growing demand for sleep disorder solutions.
Commitment to Innovation
Onera’s founder and CEO, Ruben de Francisco, emphasized the company’s dedication to advancing sleep disorder diagnosis and management. With a focus on research and development, customer success, and global expansion, Onera aims to provide valuable insights and solutions to millions of individuals affected by sleep disorders.
Leave a Reply